| 2026-04-30 |
财报披露：
美东时间 2026-04-30 盘后发布财报
|
| 2026-03-16 |
详情>>
内部人交易：
Brown Michael Jon股份减少1700.00股
|
| 2026-02-12 |
详情>>
股本变动：
变动后总股本38486.48万股
|
| 2026-02-12 |
详情>>
业绩披露：
2025年年报每股收益2.14美元,归母净利润8.36亿美元,同比去年增长45.14%
|
| 2025-10-30 |
详情>>
业绩披露：
2025年三季报(累计)每股收益1.45美元,归母净利润5.69亿美元,同比去年增长34.04%
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益0.73美元,归母净利润2.85亿美元,同比去年增长-1.62%
|
| 2025-05-01 |
详情>>
业绩披露：
2025年一季报每股收益0.27美元,归母净利润1.05亿美元,同比去年增长-28.01%
|
| 2025-03-27 |
股东大会：
将于2025-05-08召开股东大会
会议内容 ▼▲
- 1.To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders. The nominees are:
2.To ratify the selection by the Audit Committee of our Board of Directors of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
3.To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2024.
4.To approve our Amended and Restated 2015 Equity Incentive Plan (as amended and restated) to, among other things, increase the number of shares reserved for issuance thereunder by 3,400,000 shares.
5.To approve our Amended and Restated 2015 Employee Stock Purchase Plan to, among other things, increase the number of shares reserved for issuance thereunder by 8,000,000 shares.
|
| 2025-02-18 |
详情>>
业绩披露：
2022年年报每股收益0.88美元,归母净利润3.41亿美元,同比去年增长57.31%
|
| 2025-02-18 |
详情>>
业绩披露：
2024年年报每股收益1.46美元,归母净利润5.76亿美元,同比去年增长6.41%
|
| 2024-10-24 |
详情>>
业绩披露：
2023年三季报(累计)每股收益0.74美元,归母净利润2.85亿美元,同比去年增长14.35%
|
| 2024-10-24 |
详情>>
业绩披露：
2024年三季报(累计)每股收益1.08美元,归母净利润4.25亿美元,同比去年增长48.84%
|
| 2024-07-25 |
详情>>
业绩披露：
2024年中报每股收益0.73美元,归母净利润2.90亿美元,同比去年增长76.23%
|
| 2024-04-25 |
详情>>
业绩披露：
2024年一季报每股收益0.38美元,归母净利润1.46亿美元,同比去年增长201.23%
|
| 2024-04-22 |
股东大会：
将于2024-05-22召开股东大会
会议内容 ▼▲
- 1.To elect ten nominees for director, each to hold office until our 2025 annual meeting of stockholders. The nominees are:Kevin R. Sayer,Steven R. Altman,Nicholas Augustinos,Richard A. Collins,Karen Dahut,Rimma Driscoll,Mark G. Foletta,Bridgette P. Heller,Kyle Malady,Eric J. Topol, M.D.
2.To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
3.To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2023
4.To provide a non-binding, advisory vote on pay equity disclosure.
5.To provide a non-binding, advisory vote on transparency in lobbying.
|
| 2024-02-08 |
详情>>
业绩披露：
2023年年报每股收益1.40美元,归母净利润5.42亿美元,同比去年增长58.70%
|
| 2023-04-06 |
股东大会：
将于2023-05-18召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to hold office until our 2024 Annual Meeting of Stockholders presented by our Board of Directors:Steven R. Altman,Richard A. Collins,Karen Dahut,Mark G. Foletta,Barbara E. Kahn,Kyle Malady,Eric J. Topol, M.D.
2.To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
3.To hold a non-binding vote on an advisory resolution to approve executive compensation.
4.To recommend a non-binding vote on the frequency of the advisory vote on executive compensation.
5.Non-binding vote on pay equity disclosure.
|
| 2023-04-06 |
股东大会：
将于2023-05-18召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to hold office until our 2024 Annual Meeting of Stockholders presented by our Board of Directors:Steven R. Altman,Richard A. Collins,Karen Dahut,Mark G. Foletta,Barbara E. Kahn,Kyle Malady,Eric J. Topol, M.D.
2.To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
3.To hold a non-binding vote on an advisory resolution to approve executive compensation.
4.To recommend a non-binding vote on the frequency of the advisory vote on executive compensation.
5.Non-binding vote on pay equity disclosure.
|
| 2022-04-08 |
股东大会：
将于2022-05-19召开股东大会
会议内容 ▼▲
- 1.To elect four Class II directors to hold office until our 2023 Annual Meeting of Stockholders presented by our Board of Directors
2.To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
3.To hold a non-binding vote on an advisory resolution to approve executive compensation.
4.To approve the amendment and restatement of our Restated Certificate of Incorporation to (i) effect a 4:1 forward split of our Common Stock (the "Forward Stock Split") and (ii) increase the number of shares of authorized Common Stock to effectuate the Forward Stock Split.
|
| 2022-03-25 |
详情>>
拆分方案：
每1.0000股拆分成4.0000股
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-09 |
股东大会：
将于2021-05-20召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors to hold office until our 2024 Annual Meeting of Stockholders presented by our Board of Directors:
2.To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
3.To hold a non-binding vote on an advisory resolution to approve executive compensation.
4.To approve the amendment and restatement of our Certificate of Incorporation to declassify our Board of Directors.
|
| 2020-04-10 |
股东大会：
将于2020-05-21召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors to hold office until our 2023 Annual Meeting of Stockholders presented by DexCom’s Board:Richard A. Collins, Mark G. Foletta, Eric J. Topol, M.D.
2.To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.
3.To hold a non-binding vote on an advisory resolution to approve executive compensation.
4.To conduct any other business properly brought before the meeting.
|
| 2020-03-17 |
复牌提示：
2020-03-17 11:13:36 停牌，复牌日期 2020-03-17 11:18:36
|
| 2019-04-19 |
股东大会：
将于2019-05-30召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors to hold office until our 2022 Annual Meeting of Stockholders. DexCom’s Board of Directors has nominated the following persons for election as Class II directors:
2.To ratify the selection by the audit committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.
3.To hold a non-binding vote on an advisory resolution to approve executive compensation.
4.To amend our Amended and Restated 2015 Equity Incentive Plan to increase the number of shares reserved thereunder by an additional 2,200,000 shares and make certain administrative changes to such Amended and Restated 2015 Equity Incentive Plan.
5.To conduct any other business properly brought before the meeting.
|
| 2018-04-20 |
股东大会：
将于2018-05-31召开股东大会
会议内容 ▼▲
- 1. To elect three Class I directors to hold office until our 2021 Annual Meeting of Stockholders. DexCom’s Board of Directors has nominated the following persons for election as Class I directors:
Terrance H. Gregg
Kevin Sayer
Nicholas Augustinos
2. To ratify the selection by the audit committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.
3. To hold a non-binding vote on an advisory resolution to approve executive compensation.
4. To conduct any other business properly brought before the meeting.
|
| 2017-04-20 |
股东大会：
将于2017-05-31召开股东大会
会议内容 ▼▲
- 1. To elect three Class III directors to hold office until our 2020 Annual Meeting of Stockholders. DexCom’s Board of Directors has nominated the following persons for election as Class III directors:
Richard Collins
Mark Foletta
Eric J. Topol
2. To ratify the selection by the audit committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017.
3. To hold a non-binding vote on an advisory resolution to approve executive compensation.
4. To hold a non-binding advisory vote on the frequency of the advisory vote on executive compensation.
5. To amend and restate our 2015 Equity Incentive Plan to increase the number of shares reserved thereunder by an additional 3,600,000 shares and eliminate payment of dividends on unvested shares.
6. To amend our Restated Certificate of Incorporation to increase the number of authorized shares of common stock to 200,000,000 shares.
7. To conduct any other business properly brought before the meeting.
|
| 2016-04-06 |
股东大会：
将于2016-05-19召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors to hold office until our 2019 Annual Meeting of Stockholders.
2.To ratify the selection by the audit committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
3.To hold a non-binding vote on an advisory resolution to approve executive compensation.
4.To conduct any other business properly brought before the meeting.
|
| 2015-04-13 |
股东大会：
将于2015-05-28召开股东大会
会议内容 ▼▲
- 1. To elect three Class I directors to hold office until our 2018 Annual Meeting of Stockholders. DexCom’s Board of Directors has nominated the following persons for election as Class I directors:
Terrance H. Gregg
Kevin Sayer
Nicholas Augustinos
2. To ratify the selection by the audit committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015.
3. To hold a non-binding vote on an advisory resolution to approve executive compensation.
4. To approve our 2015 Equity Incentive Plan.
5. To approve our 2015 Employee Stock Purchase Plan.
6. To conduct any other business properly brought before the meeting.
|